Shareholders in a class action against failed steel giant Arrium and KPMG are seeking an unredacted version of an audit file by KPMG to probe the accounting giant’s handling of the steel producer’s financial statements before its collapse in April 2016.
The former chief financial officer of beleaguered Forum Group has been dragged into a lawsuit by Westpac seeking to recoup $294 million in funds paid into an alleged fraudulent scheme.
Two law firms are seeking court approval to drop class actions brought on behalf of allegedly misclassified casual coal miners, in light of a High Court decision that “radically” decreased their chances of success.
Professional services giant PricewaterhouseCoopers has hit back at a class action over a $50 million prospectus for Axsesstoday, filing a cross-claim against the asset finance lender and saying it “takes no responsibility” for allegedly defective offer documents.
A bid by Google for a confidentiality undertaking by former NSW Deputy Premier John Barilaro over evidence produced in the politician’s defamation case has earned a sharp rebuke by a judge.
Ashurst has picked up a leading insolvency partner from Norton Rose Fulbright who advised on the restructure of the beleagured Arrium Group.
Generic drug maker Sandoz AG has filed proceedings seeking the revocation of two patents registered in Australia by German pharmaceutical giant Bayer covering its top-selling blood clot drug Xarelto.
Honda Motors has failed to strike out or permanently stay a proceeding seeking discovery for a possible lawsuit over the Japanese car maker’s decision to abandon its Australian dealership model, with a judge rejecting Honda’s argument that the preliminary discovery application didn’t meet the requirements for service abroad.
A law firm that has filed seven class actions on behalf of casual coal mine workers is looking to discontinue two of those cases, after the High Court dealt them a serious blow by finding that those who work regular shifts are not entitled to paid leave and other entitlements under the Fair Work Act.
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.